In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab.
Jean-Philippe LolySophie VieujeanCatherine ReenaersCatherine Van KemsekeLaurence SeidelEdouard LouisJoan SomjaPublished in: Inflammatory bowel diseases (2023)
Despite endoscopic, biological, and even histological remission, we found a high prevalence of endomicroscopic abnormalities, which were not different between anti-tumor necrosis factor- and vedolizumab-treated patients. The clinical significance of these anomalies remains to be clarified.
Keyphrases
- ulcerative colitis
- newly diagnosed
- end stage renal disease
- rheumatoid arthritis
- ultrasound guided
- disease activity
- chronic kidney disease
- ejection fraction
- patients with inflammatory bowel disease
- prognostic factors
- peritoneal dialysis
- optical coherence tomography
- patient reported outcomes
- endoscopic submucosal dissection